AstraZeneca was forced to concede a clinical defeat on Monday, noting that one of its top respiratory drugs in the clinic failed a study for severe chronic obstructive pulmonary disease. But while investigators also flagged a higher rate of adverse events for benralizumab than the placebo arm, the pharma giant shows no signs of backing away from a treatment it's billed as a potential $2 billion per year product.
AstraZeneca has launched a Phase III test of its targeted IL-13 asthma drug tralokinumab, beefing up its late-stage pipeline for respiratory diseases and squaring off against some major league competition now in the clinic.
Drugmakers cheer when influential doctors' groups revise treatment guidelines to include new drugs. But as AstraZeneca's MedImmune unit knows, those groups can backpedal.
AstraZeneca's flu vaccine sales may have just gotten a boost, courtesy of federal regulators. Wednesday, they recommended that healthy children 2 to 8 years old receive the company's nasal spray flu vaccine FluMist in lieu of flu shots when available.
Roche's Ventana Medical Systems and MedImmune said they will jointly develop an assay to help test a MedImmune immunotherapy for non-small cell lung cancer.
With Pfizer pounding on the door amid a full-blown ruckus in Parliament, AstraZeneca took another step forward in its quest to quickly advance its high-profile immuno-oncology program for MEDI4736.
AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.
MD Anderson's popular "moon-shot" immuno-oncology research project has won over another big industry player looking to play catch-up in the hottest race in cancer drug R&D. AstraZeneca's biologics arm, MedImmune, has become the latest Big Pharma player to join a team that has already attracted Pfizer and J&J.
MedImmune, AstraZeneca's biologics arm, had inked a three-year agreement with the University of California, San Francisco, tapping the school's roster of scientists with hopes of finding promising projects across a bevy of disease areas.
Immunocore's list of collaborators is beginning to look like a Who's Who in Big Pharma. Today the biotech--which is developing T cell immunotherapy technology originally spun out of Oxford--added a deal-hungry AstraZeneca and its biologics team at MedImmune as its latest partner, which will now join Genentech and GlaxoSmithKline in exploring whether the biotech has really found a powerful new approach to engineering an immune system attack on cancer cells.